Linezolida Altan

Linezolid, the active ingredient in Linezolida Altan, is a oxazolidinone antibiotic presented as an intravenous formulation for hospital use. It treats serious bacterial infections, including skin and soft‑tissue infections, pneumonia, and infections caused by resistant Gram‑positive organisms.

GNH USA supplies Linezolida Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacy networks worldwide, with a focus on quality assurance and regulatory compliance.

Linezolid is indicated for several serious bacterial infections affecting the skin, lungs and resistant Gram‑positive pathogens. - Complicated skin and soft tissue infections: effective against Gram‑positive bacteria, helping to resolve infection and promote healing. - Community‑acquired and nosocomial pneumonia: reduces bacterial load in the lungs, improving respiratory function. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides an alternative to vancomycin for resistant strains. - Vancomycin‑resistant Enterococcus (VRE) infections: active against VRE, supporting infection control in hospital settings.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome - Lactic acidosis

When using Linezolida Altan, several precautions should be observed to ensure safety. - Monitor blood counts: perform regular complete blood count to detect thrombocytopenia or anemia. - Assess renal function: adjust therapy in patients with significant renal impairment. - Evaluate for serotonergic agents: avoid concomitant use with MAO inhibitors or SSRIs due to serotonin syndrome risk. - Use caution in hepatic impairment: consider dose adjustment and monitor liver enzymes. - Limit duration of therapy: prolonged use increases risk of neuropathy and hematologic effects. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linezolid can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increase risk of serotonin syndrome. - Rifampin: induces metabolism, markedly lowering linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use may increase bleeding risk. - Cyclosporine: may increase nephrotoxicity; monitor renal function.